Anthony Hunt - Sep 10, 2024 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Role
Director
Signature
/s/ Jennifer Carmichael (Attorney in Fact)
Stock symbol
RGEN
Transactions as of
Sep 10, 2024
Transactions value $
-$2,887,227
Form type
4
Date filed
9/12/2024, 11:35 AM
Previous filing
Sep 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGEN Common Stock Options Exercise $339K +10K +6.58% $33.87 162K Sep 10, 2024 Direct
transaction RGEN Common Stock Sale -$215K -1.5K -0.92% $143.77 161K Sep 10, 2024 Direct F1, F2
transaction RGEN Common Stock Sale -$1.36M -9.37K -5.84% $144.88 151K Sep 10, 2024 Direct F1, F3
transaction RGEN Common Stock Sale -$1.57M -10.7K -7.09% $145.95 140K Sep 10, 2024 Direct F1, F4
transaction RGEN Common Stock Sale -$88.6K -604 -0.43% $146.67 140K Sep 10, 2024 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGEN Stock Option (Right to Buy) Options Exercise $0 +10K +70.2% $0.00 24.2K Sep 10, 2024 Common Stock 10K $33.87 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023.
F2 $143.77 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.44 to $144.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 $144.88 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.45 to $145.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 $145.95 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.49 to $146.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 $146.67 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.49 to $146.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 This option is fully vested and exercisable.